American Venous Forum

Inari Medical Announces Interim Two-Year Results from the ClotTriever CLOUT Registry

Retrieved on: 
화요일, 3월 12, 2024
Deep vein thrombosis, Pulmonary embolism, VTE, Incidence, Sequela, CAVA, Patient, Post-thrombotic syndrome, Research, PTS, DVT, Randomized controlled trial, Safety, FACS, American Venous Forum, Data, Pharmaceutical industry

IRVINE, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced positive two-year interim results from the CLOUT registry.

Key Points: 
  • IRVINE, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced positive two-year interim results from the CLOUT registry.
  • The interim results are the largest prospective, multi-center two-year dataset in deep vein thrombosis (DVT) since the ATTRACT trial and confirm the excellent safety, effectiveness, and long-term outcomes of the ClotTriever system in real-world DVT patients.
  • Patients had low incidence of independently adjudicated safety events related to rethrombosis, with only 5.0% and 8.4% at 30-days and 6 months, respectively.
  • We remain committed to establishing the ClotTriever and FlowTriever systems as standard of care for deep vein thrombosis and pulmonary embolism (PE) patients.”

New Viz.ai Study Demonstrates Reduced Mortality Rates in Patients with Pulmonary Embolism

Retrieved on: 
목요일, 3월 7, 2024
Software, General Health, Professional Services, Data Management, Medical Devices, Technology, Infectious Diseases, Hospitals, Artificial Intelligence, Health Technology, Data Analytics, Health, Viz, Pulmonary embolism, Multimedia, AI, AVF, Assessment, TriHealth, Mortality, American Venous Forum, PERT, Medical device

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced clinical data validating the impact of the Viz PE Solution in the management and outcomes of patients with pulmonary embolism (PE).

Key Points: 
  • Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced clinical data validating the impact of the Viz PE Solution in the management and outcomes of patients with pulmonary embolism (PE).
  • The data was presented during the 2024 AVF (American Venous Forum) by Jacob Shapiro, M.D., vascular surgeon at TriHealth in Cincinnati, OH.
  • View the full release here: https://www.businesswire.com/news/home/20240307999862/en/
    The real-world study, "Shorter Time to Assessment and Anticoagulation with Decreased Mortality in Patients with Pulmonary Embolism Following Implementation of Artificial Intelligence Software," evaluated the clinical impact of the Viz PE Solution on time to assessment, time to anticoagulation, and patient outcomes at TriHealth.
  • The study found that implementation of the AI-powered solution combined with PERT activation significantly improved time to assessment and time to anticoagulation with a 74% reduction in in-hospital mortality risk.

Society for Vascular Surgery Vascular Quality Initiative Reaches Milestone 1,000 Centers Mark

Retrieved on: 
화요일, 4월 11, 2023
Health Technology, Data Management, Manufacturing, Other Health, Technology, Pharmaceutical, Surgery, Practice Management, General Health, Hospitals, Clinical Trials, Cardiology, Other Manufacturing, Software, Health, Volunteering, Database, ACC, SVS, Partnership, Society, American Heart Association, Registry, SVU, Data collection, American College of Cardiology, Radiology, Society for Vascular Medicine, AHA, SVM, Organization, Medicare, Patient, American Venous Forum, Growth, VASA, American College, Fivos Constantinou, AVF, Safety, Program director, Medical imaging, Pharmaceutical industry, Medical device, Mobile phone, MD

The Society for Vascular Surgery® Vascular Quality Initiative® (SVS VQI) clinical registry announced today it has achieved another milestone with more than 1,000 centers enlisted in VQI registries—an achievement that will strengthen vascular care, improve outcomes, and underscore the value of real-world data in analyzing outcomes and reducing resource utilization.

Key Points: 
  • The Society for Vascular Surgery® Vascular Quality Initiative® (SVS VQI) clinical registry announced today it has achieved another milestone with more than 1,000 centers enlisted in VQI registries—an achievement that will strengthen vascular care, improve outcomes, and underscore the value of real-world data in analyzing outcomes and reducing resource utilization.
  • This long list of SVS VQI participating centers reflects their commitment to quality.
  • Individuals completing their medical residencies or fellowships in any vascular disease-focused specialty (e.g., vascular surgery, cardiology, radiology, vascular medicine) may participate in the 12- to 18-month program.
  • The program fosters an understanding of quality processes and metrics among vascular residents and fellows through mentorship in the VQI, in collaboration with the Association of Program Directors in Vascular Surgery (APDVS), American College of Cardiology, and Society for Vascular Medicine.